The CDKN1A gene encoding a cell cycle inhibitor, p21(WAF1/CIP1), is located in the systemic lupus erythematosus (SLE) susceptibility locus on chromosome 6p21.2. Decreased cellular levels of p21 are associated with SLE. Here, we examine four single-nucleotide polymorphisms (SNPs) within the promoter and two in the first intron of CDKN1A for association with SLE susceptibility. A comparison of 742 Korean SLE patients with 1017 controls disclosed that one SNP (rs762624 C4A at position À899), located at a putative Myb-binding site in the promoter, was associated with SLE susceptibility (P ¼ 0.00047). This association was independent of the SLE-association signal of HLA-DRB1 on 6p21.3, as it was significant after adjustment for SLE-risk DRB1 alleles (P ¼ 0.0012). The same SNP was associated with lupus nephritis (P ¼ 0.000014). The risk allelecarrying promoter sequence displayed B15% lower activity than the non-risk sequence upon fusion to the luciferase gene (P ¼ 0.025). Endogenous CDKN1A mRNA levels measured in Epstein-Barr virus-transformed B cells established from 16 control subjects were linearly correlated with a decreasing copy number of the risk allele (P ¼ 0.024). Accordingly, we conclude that the minor allele A at À899 of CDKN1A is associated with increased susceptibility to SLE and lupus nephritis, and decreased cellular levels of p21.
Introduction
Systemic lupus erythematosus (SLE; OMIM 152700) is a chronic autoimmune disease with clinically diverse and variable manifestations, which is affected by multiple genetic and environmental factors. 1, 2 The SLE patient's immune system produces autoantibodies mostly against molecules in the cell nucleus, such as DNA, histone and RNA-binding proteins. 3 These nuclear antigens are derived mostly from apoptosis, and ignored in the normal immune system. In SLE, however, the immune tolerance to self fails. When nuclear apoptotic products are presented by antigen-presenting cells in SLE, lupus T-helper cells are improperly activated due to a lowered threshold of stimuli, resulting in the production of anti-nuclear autoantibodies by plasma B cells. 4, 5 The immune complexes formed between autoantibodies and self-antigens are deposited in the organs, and mediate inflammation to damage the organ. 3, 5 Several factors contribute to the immune tolerance breakdown in SLE, although no single factor is deterministic. Hyperactivation and enhanced proliferation of T and B cells, hyperactivation of antigen-presenting cells, defective generation of induced regulatory T cells, and increased levels of apoptotic products are among the factors involved in SLE autoimmunity. [5] [6] [7] Systemic lupus erythematosus is a complex disease as multiple genes influence disease susceptibility. Among the several candidate genes, CDKN1A was tested in particular for association with SLE susceptibility in this study, as it is located on 6p21, which displays the most significant link with SLE susceptibility in genome-wide association studies. [8] [9] [10] [11] The expression levels of CDKN1A were considerably lower in SLE patients than in healthy controls. 12 Furthermore, lupus-like phenotype was observed in p21 knockout mice. 6 We examined six singlenucleotide polymorphisms (SNPs) in CDKN1A that potentially affect expression levels for functional association with susceptibility to SLE. Consequently, one promoter SNP associated with both the expression and SLE susceptibility was identified.
Results
Association of CDKN1A SNP rs762624 at position À899 with SLE susceptibility In total, 742 unrelated Korean patients with SLE and 1017 non-patient controls were recruited for this case-control study on SLE susceptibility. Earlier studies show that decreased or abolished cellular levels of p21 are associated with SLE. 6, 12, 13 To determine the regulatory polymorphisms related to gene expression and SLE susceptibility, patients and controls were compared with respect to individual genotypes of six SNPs in CDKN1A, including four SNPs in the promoter and two in the first intron (Table 1) . Among them, only SNP rs762624 at position À899 was associated with susceptibility to SLE. The minor allele A was significantly associated with 1.25-fold increased susceptibility to SLE versus the major allele C (P ¼ 0.0019). Minor allele-carrying genotypes conferred 1.43-fold increased susceptibility versus the major allele homozygotes (P ¼ 0.00047). In contrast, all the other five SNPs (rs733590 at position À1284, rs762623 at À1021, rs2395655 at À791, rs3176330 at þ 1004 and rs3176343 at þ 3781) were not associated with SLE susceptibility (Table 1) or tightly linked to the associated SNP rs762624 (r 2 p0.24). Both CDKN1A (6p21.2) and HLA-DRB1 (6p21.3) are located on chromosome 6p21, which is significantly linked to SLE. To determine whether the observed association of CDKN1A SNP simply reflects tight linkage to risk alleles in HLA-DRB1, we performed logistic regression analysis with adjustment for carriage of the four SLE-risk alleles of DRB1 *0701, *0803, *0901 or *1501.
14 SLE association of the SNP at À899 was still significant (P ¼ 0.0012), with an odds ratio of 1.31 and 95% confidence interval of 1.12À1.55, independent of the SLE risk alleles in HLA-DRB1.
Association of CDKN1A SNP rs762624 at À899 with lupus nephritis The SNP at position À899 was also significantly associated with lupus nephritis (LN), one of the most serious manifestations of SLE (Table 2) . A comparison of LN-positive patients with non-SLE control subjects (P ¼ 0.000014 in a dominant model) or LN-negative patients (P ¼ 0.0072 in a dominant model) confirmed significant genotypic association.
Association of SNP rs762624 at À899 with CDKN1A transcript levels The SLE-and LN-associated SNP (C4A) is located at the second residue of a putative binding site of the transcription factor c-Myb (CCGTTT from À900 to À895), and induces differential allelic binding in electrophoretic mobility shift assays using HeLa and Jeg-3 cell nuclear extracts. 15 The SNP change of C to A within the hexamer core of the Myb recognition element caused a dramatic decrease in gene expression in vivo. 16, 17 On fusion of a promoter sequence from positions À2326 to þ 17 with C or A at À899 to the luciferase gene, the promoter sequence with the risk allele A displayed B15% lower activity than that with the non-risk allele C in both U937 (P ¼ 0.027) and HeLa (P ¼ 0.025) cells ( Figure 1) .
Additionally, the levels of endogenous CDKN1A transcripts in Epstein-Barr virus-transformed B cells derived from 16 non-patient donors were measured by real-time reverse-transcriptase PCR (Figure 2 ). The mRNA levels were significantly correlated with the individual's copy of the risk allele in linear regression analyses (P ¼ 0.024, R 2 ¼ 0.31). Transcript levels in AA homozygotes were lower than those in CA heterozygotes, which, in turn, were lower than those in CC homozygotes.
Discussion
This is the first finding that the minor allele A of the SNP (position À899) at a putative Myb-binding site of the CDKN1A promoter is associated with decreased cellular levels of mRNA and increased susceptibility to SLE as well as LN. Although these associations need to be confirmed in other independent cohorts, they are functionally relevant to recent reports suggesting that a low level or deficiency of p21 is involved in SLE development and phenotype. The p21 level in phytohemagglutinin-stimulated peripheral blood lymphocytes was about 3-fold lower in SLE patients than in control subjects. 12 In mouse studies, p21-deficient mice displayed a lupus-like phenotype, 6 and a peptidyl mimic of p21 attenuated the symptoms of murine lupus.
13
CDKN1A encodes the cyclin-dependent kinase inhibitor, p21(WAF1/CIP1), which prevents DNA replication/ proliferation and induces G1 arrest by direct binding to the cyclin-CDK complex and proliferating-cell nuclear Position numbers are relative to the transcription start site (+1) of CDKN1A.
SLE-associated SNP in the CDKN1A promoter K Kim et al antigen. 18 In the immune system, p21 appears to regulate lymphocyte activation and homeostatic proliferation, as its deficiency enhances proliferation and hyperresponsiveness of memory or activated T-cells. 19 We suggest that the reduced production of p21 by the minor allele A of the À899 SNP is one of the genetic factors contributing to dysregulation of lymphocyte homeostasis and immune tolerance.
Kong et al. 20 showed an association of two SNPs (rs4135234 and rs762623) in the CDKN1A promoter with SLE susceptibility in a Hong Kong Chinese population. One of these two SNPs, rs762623, was not associated with SLE susceptibility in Koreans (Table 1) . This allelic heterogeneity may result from the differences in allele frequency, linkage disequilibrium structure or causal variants among different ethnic populations. For example, the minor allele frequency of rs762623 in control subjects appears to vary markedly among different populations, specifically, 6.7% in Hong Kong Chinese, 20 7.5% in sub-Saharan Africans (HapMap YRI), 11.1% in Han Chinese (HapMap HCB), 12.2% in Koreans (this study), 13.3% in European Caucasians (HapMap CEU) and 21.1% in Japanese (HapMap JPT). Furthermore, SNPs in the CDKN1A promoter region do not appear to be tightly linked to each other in several ethnic populations (r 2 p0.33 in Koreans). Thus, the associations of rs762624 and other SNPs in the CDKN1A promoter require further testing in other ethnic populations.
In conclusion, the CDKN1A gene is associated with susceptibility to SLE and LN, irrespective of HLA-DRB1 alleles. Moreover, increased susceptibility is attributed to allele A in a promoter SNP at position À899. The risk allele A decreased affinity for a transcription factor (most likely c-Myb) versus the non-risk allele C, leading to suppression of promoter activity, and reduced cellular levels of p21 associated with SLE. In each individual, the CDKN1A mRNA level was normalized to that of GAPDH mRNA. All measurements were carried out in triplicate. Genotyping Single-nucleotide polymorphism genotyping was carried out for subjects by homogenous MassEXTEND reactions using the MassARRAY system (Sequenom, San Diego, CA, USA), according to the manufacturer's instructions. HLA-DRB1 was genotyped for 478 SLE patients and 1017 controls using the PCR-sequencing-based typing method, as described earlier. 14 
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Cell culture
Human histolytic lymphoma U937 and Epstein-Barr virus-transformed B cells were cultured in the RPMI 1640 medium (Gibco, Rockville, MD, USA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM HEPES, 1.0 mM sodium pyruvate and 1% penicillin/streptomycin. Human cervical adenocarcinoma HeLa cells were maintained in Dulbecco's modified Eagle's medium (Gibco) with 10% fetal bovine serum, 4 mM L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose and 1% penicillin/streptomycin. The cells were grown in 5% CO 2 at 37 1C under a humidified atmosphere.
Plasmid construction and dual-luciferase reporter assays A CDKN1A promoter sequence from positions À2326 to þ 17, containing the non-risk allele C of rs762624, was amplified using primers 5 0 -AATGCTAGCTGCCTGCTTC CCAGGAACATGCT-3 0 (forward) and 5 0 -CCTAAGCTTT GCTCACACCTCAGCTGGCGCA-3 0 (reverse). The other promoter variant carrying the risk allele A was generated by site-directed mutagenesis using overlapping extension PCR. The amplified products were digested with NheI and HindIII, and ligated into pGL3-basic vector (Promega, Madison, WI, USA) containing a luciferasecoding region without a promoter. The correct constructs were confirmed by sequencing analyses.
For luciferase reporter assays, U937 and HeLa cells were transfected with one of the pGL3 constructs and pRL-TK vector (Promega) in serum-free medium for 6 h, using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA). After transfection, cells were cultured in complete medium for 36 h, harvested and lysed in passive lysis buffer (Promega). Luciferase activity was measured using the dual-luciferase reporter assay system (Promega). All experiments were carried out in triplicate.
Quantitative real-time polymerase chain reactions Endogenous CDKN1A and GAPDH mRNA levels were measured in Epstein-Barr virus-transformed B cell lines derived from 16 healthy people. Total RNA was extracted from the B cell lines using an RNeasy Mini Kit (Qiagen, Hilden, Germany), and cDNAs were synthesized using random hexamers and Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Quantitative realtime PCR and data analyses were performed using the iQ SYBR Green Supermix and iCycler iQ5 machine (BioRad, Hercules, CA, USA) in three independent experiments. The primers used were 5 0 -CCATGTGGACCTGTC ACTGT-3 0 (CDKN1A forward), 5 0 -GGCAGAAGATGTAG AGCGG-3 0 (CDKN1A reverse), 5 0 -GTCGCCAGCCGAGC CACATC-3 0 (GAPDH forward) and 5 0 -TGTAGTTGAGGT CAATGAAG-3 0 (GAPDH reverse). The CDKN1A mRNA levels were normalized to that of GAPDH mRNA.
Statistical analyses and linkage disequilibrium calculation
Hardy-Weinberg equilibrium and SNP's association with SLE susceptibility or clinical features were assessed using w 2 tests. The linkage disequilibrium pattern was analyzed using the Haploview 4.1 program. Logistic regression analysis was performed to calculate the odds ratio at a 95% confidence interval adjusted for the risk alleles of HLA-DRB1. In a luciferase reporter assay, data were analyzed using one-way analysis of variance. All statistical analyses were performed using SPSS 11.5.
